J Am Coll Cardiol:采用连续热稀释法测定冠脉疾病患者的**冠脉血流量

2021-03-04 MedSci原创 MedSci原创

冠状动脉内连续热稀释法是一种量化冠状动脉绝对血流量(Q)和阻力(R)的新技术

冠状动脉内连续热稀释法是一种量化冠状动脉绝对血流量(Q)和阻力(R)的新技术,与冠状动脉血流储备(CFR)和微血管阻力指数(IMR)等现有方法相比具有潜在的优势。然而,目前还没有关于缺血性和非梗阻性冠状动脉疾病(INOCA)患者的相关数据。

连续热稀释法检测示例

本研究旨在评估INOCA患者连续热稀释法检测的Q和R与已建立的CFR/IMR的关系,探讨Q绝对值的潜力,并预测自报性心绞痛。

共纳入了84例INOCA患者(87%女性,平均年龄56±8岁),予以冠状动脉功能检测,包括乙酰胆碱(ACH)激发试验、腺苷(ADE)试验(CFR/IMR)和连续热稀释(绝对值Q和R)伴盐水诱导性充血。

根据ACH和ADE检测的绝对冠脉血流和阻力

ACH检测的异常率为87%,ADE检测的异常率为38%。Q的绝对中位值为198ml/min,R的绝对中位值为416WU。ADE检测异常的患者的绝对R值高于ADE检测正常的患者(495WU vs 375WU;P=0.04),但ACH检测异常和ACH检测正常的患者之间没有差异(421WU vs 409WU;P=0.74)。

Q、R、CFR和IMR对心绞痛的预测价值

低Q和高R值均与严重心绞痛相关(优势比[OR]分别为:3.09,95%CI 1.16~8.28,P=0.03;和2.60,0.99~6.81,P=0.05)。

在本研究中,CFR/IMR异常的患者的R绝对值较高,但Q和R与冠状动脉血管痉挛均无关。Q和R与心绞痛相关,不过它们的确切预测价值还应该在更大的研究中进一步确定。

原始出处:

Konst Regina E,Elias-Smale Suzette E,Pellegrini Dario et al. Absolute Coronary Blood Flow Measured by Continuous Thermodilution in Patients With Ischemia and Nonobstructive Disease. J Am Coll Cardiol, 2021, 77: 728-741.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2075910, encodeId=571a20e59109a, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat May 22 11:31:31 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782119, encodeId=6a7c1e82119ce, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 16 05:31:31 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799146, encodeId=d66b1e99146f5, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue May 04 12:31:31 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783382, encodeId=2c0a1e833821e, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Nov 27 23:31:31 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662333, encodeId=517d16623335e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Sat Jun 12 23:31:31 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486599, encodeId=b94d148659995, content=<a href='/topic/show?id=47eb6e242ba' target=_blank style='color:#2F92EE;'>#热稀释法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67242, encryptionId=47eb6e242ba, topicName=热稀释法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598178251, createdName=bshuang, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572989, encodeId=ddd515e2989b1, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2075910, encodeId=571a20e59109a, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat May 22 11:31:31 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782119, encodeId=6a7c1e82119ce, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 16 05:31:31 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799146, encodeId=d66b1e99146f5, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue May 04 12:31:31 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783382, encodeId=2c0a1e833821e, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Nov 27 23:31:31 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662333, encodeId=517d16623335e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Sat Jun 12 23:31:31 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486599, encodeId=b94d148659995, content=<a href='/topic/show?id=47eb6e242ba' target=_blank style='color:#2F92EE;'>#热稀释法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67242, encryptionId=47eb6e242ba, topicName=热稀释法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598178251, createdName=bshuang, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572989, encodeId=ddd515e2989b1, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2075910, encodeId=571a20e59109a, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat May 22 11:31:31 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782119, encodeId=6a7c1e82119ce, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 16 05:31:31 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799146, encodeId=d66b1e99146f5, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue May 04 12:31:31 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783382, encodeId=2c0a1e833821e, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Nov 27 23:31:31 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662333, encodeId=517d16623335e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Sat Jun 12 23:31:31 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486599, encodeId=b94d148659995, content=<a href='/topic/show?id=47eb6e242ba' target=_blank style='color:#2F92EE;'>#热稀释法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67242, encryptionId=47eb6e242ba, topicName=热稀释法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598178251, createdName=bshuang, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572989, encodeId=ddd515e2989b1, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2075910, encodeId=571a20e59109a, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat May 22 11:31:31 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782119, encodeId=6a7c1e82119ce, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 16 05:31:31 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799146, encodeId=d66b1e99146f5, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue May 04 12:31:31 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783382, encodeId=2c0a1e833821e, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Nov 27 23:31:31 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662333, encodeId=517d16623335e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Sat Jun 12 23:31:31 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486599, encodeId=b94d148659995, content=<a href='/topic/show?id=47eb6e242ba' target=_blank style='color:#2F92EE;'>#热稀释法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67242, encryptionId=47eb6e242ba, topicName=热稀释法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598178251, createdName=bshuang, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572989, encodeId=ddd515e2989b1, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=)]
    2021-11-27 waiwai3030
  5. [GetPortalCommentsPageByObjectIdResponse(id=2075910, encodeId=571a20e59109a, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat May 22 11:31:31 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782119, encodeId=6a7c1e82119ce, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 16 05:31:31 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799146, encodeId=d66b1e99146f5, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue May 04 12:31:31 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783382, encodeId=2c0a1e833821e, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Nov 27 23:31:31 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662333, encodeId=517d16623335e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Sat Jun 12 23:31:31 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486599, encodeId=b94d148659995, content=<a href='/topic/show?id=47eb6e242ba' target=_blank style='color:#2F92EE;'>#热稀释法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67242, encryptionId=47eb6e242ba, topicName=热稀释法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598178251, createdName=bshuang, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572989, encodeId=ddd515e2989b1, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=)]
    2021-06-12 丁鹏鹏
  6. [GetPortalCommentsPageByObjectIdResponse(id=2075910, encodeId=571a20e59109a, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat May 22 11:31:31 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782119, encodeId=6a7c1e82119ce, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 16 05:31:31 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799146, encodeId=d66b1e99146f5, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue May 04 12:31:31 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783382, encodeId=2c0a1e833821e, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Nov 27 23:31:31 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662333, encodeId=517d16623335e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Sat Jun 12 23:31:31 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486599, encodeId=b94d148659995, content=<a href='/topic/show?id=47eb6e242ba' target=_blank style='color:#2F92EE;'>#热稀释法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67242, encryptionId=47eb6e242ba, topicName=热稀释法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598178251, createdName=bshuang, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572989, encodeId=ddd515e2989b1, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2075910, encodeId=571a20e59109a, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat May 22 11:31:31 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782119, encodeId=6a7c1e82119ce, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun May 16 05:31:31 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799146, encodeId=d66b1e99146f5, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue May 04 12:31:31 CST 2021, time=2021-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783382, encodeId=2c0a1e833821e, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Nov 27 23:31:31 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662333, encodeId=517d16623335e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Sat Jun 12 23:31:31 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486599, encodeId=b94d148659995, content=<a href='/topic/show?id=47eb6e242ba' target=_blank style='color:#2F92EE;'>#热稀释法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67242, encryptionId=47eb6e242ba, topicName=热稀释法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2598178251, createdName=bshuang, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572989, encodeId=ddd515e2989b1, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Sat Mar 06 13:31:31 CST 2021, time=2021-03-06, status=1, ipAttribution=)]

相关资讯

JACC:铂铬合金依维莫司洗脱支架用于冠脉疾病的长期安全性和疗效

经过5年的随访,PtCr-EES显示出与CoCr-EES相当的安全性和疗效,支架血栓形成率及其他不良事件发生率低。

EuroIntervention:肥胖悖论——BMI的适度增加与PCI后患者生存率的改善相关

本研究旨在评估接受经皮血管重建术的冠状动脉疾病患者的体重指数(BMI)与结局之间的关系。

Circulation:早绝经是克隆性造血和冠脉疾病的独立风险因素!

早绝经,女性心血管疾病和克隆性造血风险增加!

JAHA:经导管主动脉瓣植入心肌血运重建的生理vs.血管造影引导

在这项观察性研究中,FFR引导与经导管主动脉瓣植入患者较好的预后相关。

Front Bioeng Biotechnol:新型植入支架可更好的防止血栓形成和支架内再狭窄

植入支架是治疗冠状动脉疾病最有效、最微创的技术,但支架血栓形成(ST)和支架内再狭窄(IRS)的风险阻碍了愈合过程。市场上的支架种类繁多,但以临时性的设计图案为主。目前仍需要一种系统的设计方法,以提高

JAMA Cardiol:银屑病中主动脉血管炎症与冠脉斑块特征的关联

主动脉VI与广泛的CAD指标相关,提示了主动脉VI可能是早期CAD的替代指标。